Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt 22.70
CBPO's Cash-to-Debt is ranked higher than
85% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. CBPO: 22.70 )
Ranked among companies with meaningful Cash-to-Debt only.
CBPO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.65  Med: 7.33 Max: No Debt
Current: 22.7
Equity-to-Asset 0.77
CBPO's Equity-to-Asset is ranked higher than
61% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CBPO: 0.77 )
Ranked among companies with meaningful Equity-to-Asset only.
CBPO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.29  Med: 0.59 Max: 0.77
Current: 0.77
0.29
0.77
Interest Coverage 629.73
CBPO's Interest Coverage is ranked lower than
66% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CBPO: 629.73 )
Ranked among companies with meaningful Interest Coverage only.
CBPO' s Interest Coverage Range Over the Past 10 Years
Min: 6.9  Med: 49.91 Max: 629.73
Current: 629.73
6.9
629.73
Piotroski F-Score: 5
Altman Z-Score: 14.82
Beneish M-Score: -2.17
WACC vs ROIC
12.43%
35.04%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 41.74
CBPO's Operating Margin % is ranked higher than
94% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. CBPO: 41.74 )
Ranked among companies with meaningful Operating Margin % only.
CBPO' s Operating Margin % Range Over the Past 10 Years
Min: 21.04  Med: 43.13 Max: 50.82
Current: 41.74
21.04
50.82
Net Margin % 31.29
CBPO's Net Margin % is ranked higher than
93% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. CBPO: 31.29 )
Ranked among companies with meaningful Net Margin % only.
CBPO' s Net Margin % Range Over the Past 10 Years
Min: 1.86  Med: 25.44 Max: 31.29
Current: 31.29
1.86
31.29
ROE % 22.89
CBPO's ROE % is ranked higher than
94% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. CBPO: 22.89 )
Ranked among companies with meaningful ROE % only.
CBPO' s ROE % Range Over the Past 10 Years
Min: 5.04  Med: 28.3 Max: 42.37
Current: 22.89
5.04
42.37
ROA % 17.54
CBPO's ROA % is ranked higher than
95% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. CBPO: 17.54 )
Ranked among companies with meaningful ROA % only.
CBPO' s ROA % Range Over the Past 10 Years
Min: 1.84  Med: 16.41 Max: 24.56
Current: 17.54
1.84
24.56
ROC (Joel Greenblatt) % 56.76
CBPO's ROC (Joel Greenblatt) % is ranked higher than
92% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. CBPO: 56.76 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CBPO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 56.76  Med: 78.25 Max: 197.79
Current: 56.76
56.76
197.79
3-Year Revenue Growth Rate 19.30
CBPO's 3-Year Revenue Growth Rate is ranked higher than
71% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. CBPO: 19.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CBPO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 8.3  Med: 18.1 Max: 57.4
Current: 19.3
8.3
57.4
3-Year EBITDA Growth Rate 18.70
CBPO's 3-Year EBITDA Growth Rate is ranked higher than
70% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. CBPO: 18.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CBPO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 5.5  Med: 24.3 Max: 72.7
Current: 18.7
5.5
72.7
3-Year EPS without NRI Growth Rate 24.00
CBPO's 3-Year EPS without NRI Growth Rate is ranked higher than
77% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. CBPO: 24.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CBPO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -12.9  Med: 26.4 Max: 153
Current: 24
-12.9
153
» CBPO's 30-Y Financials

Financials (Next Earnings Date: 2017-08-04 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

CBPO Guru Trades in Q2 2016

Steven Cohen 31,100 sh (New)
Manning & Napier Advisors, Inc 52,300 sh (New)
George Soros 236,700 sh (+58.12%)
Paul Tudor Jones Sold Out
Matthews Asia Small Companies Fund Sold Out
Jim Simons 229,000 sh (-38.06%)
» More
Q3 2016

CBPO Guru Trades in Q3 2016

Steven Cohen 48,200 sh (+54.98%)
Manning & Napier Advisors, Inc 80,350 sh (+53.63%)
Jim Simons 262,100 sh (+14.45%)
George Soros Sold Out
» More
Q4 2016

CBPO Guru Trades in Q4 2016

Manning & Napier Advisors, Inc 89,900 sh (+11.89%)
Jim Simons 146,496 sh (-44.11%)
Steven Cohen 22,500 sh (-53.32%)
» More
Q1 2017

CBPO Guru Trades in Q1 2017

Jim Simons 249,000 sh (+69.97%)
Steven Cohen Sold Out
Manning & Napier Advisors, Inc 82,325 sh (-8.43%)
» More
» Details

Insider Trades

Latest Guru Trades with CBPO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:NKTR, OTCPK:BTGGF, NYSE:XON, NAS:ICPT, NAS:BLUE, NAS:ACAD, OTCPK:ABCZY, NAS:JUNO, NAS:SAGE, NAS:RARE, NAS:LGND, NAS:AGIO, NAS:CLVS, NYSE:AXON, NAS:PTLA, NAS:PRTA, NAS:KITE, NAS:TBPH, OTCPK:MPSYY, NAS:TECH » details
Traded in other countries:0CB.Germany, CBPO.Mexico,
Headquarter Location:China
China Biologic Products Inc is a biopharmaceutical company is engaged in the research, development, manufacturing and sales of plasma-based pharmaceutical products to hospitals and inoculation centers directly or through distributors in China.

China Biologic Products is a biopharmaceutical company principally engaged in the research, development, manufacturing and sales of human plasma-based products in China. The company operates its business through two majority owned subsidiaries, Shandong Taibang and Guizhou Taibang. China Biologic's product pipeline includes a variety of dosages across multiple product categories. Its principal products are human albumin and immunoglobulin for intravenous injection. All of the company's products are prescription medicines administered in the form of injections. China Biologic's sales model focuses on direct sales to hospitals and inoculation centers and is complemented by distributor sales.

Ratios

vs
industry
vs
history
PE Ratio 28.93
CBPO's PE Ratio is ranked higher than
52% of the 240 Companies
in the Global Biotechnology industry.

( Industry Median: 28.38 vs. CBPO: 28.93 )
Ranked among companies with meaningful PE Ratio only.
CBPO' s PE Ratio Range Over the Past 10 Years
Min: 2.92  Med: 19.74 Max: 129.2
Current: 28.93
2.92
129.2
PE Ratio without NRI 28.93
CBPO's PE Ratio without NRI is ranked higher than
53% of the 234 Companies
in the Global Biotechnology industry.

( Industry Median: 29.63 vs. CBPO: 28.93 )
Ranked among companies with meaningful PE Ratio without NRI only.
CBPO' s PE Ratio without NRI Range Over the Past 10 Years
Min: 2.92  Med: 19.74 Max: 129.2
Current: 28.93
2.92
129.2
Price-to-Owner-Earnings 80.90
CBPO's Price-to-Owner-Earnings is ranked lower than
66% of the 138 Companies
in the Global Biotechnology industry.

( Industry Median: 35.58 vs. CBPO: 80.90 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
CBPO' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.47  Med: 33.48 Max: 81.36
Current: 80.9
5.47
81.36
PB Ratio 6.09
CBPO's PB Ratio is ranked lower than
69% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. CBPO: 6.09 )
Ranked among companies with meaningful PB Ratio only.
CBPO' s PB Ratio Range Over the Past 10 Years
Min: 0.84  Med: 3.44 Max: 11.71
Current: 6.09
0.84
11.71
PS Ratio 8.78
CBPO's PS Ratio is ranked higher than
60% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. CBPO: 8.78 )
Ranked among companies with meaningful PS Ratio only.
CBPO' s PS Ratio Range Over the Past 10 Years
Min: 0.68  Med: 2.93 Max: 12.76
Current: 8.78
0.68
12.76
Price-to-Free-Cash-Flow 45.76
CBPO's Price-to-Free-Cash-Flow is ranked lower than
64% of the 141 Companies
in the Global Biotechnology industry.

( Industry Median: 24.99 vs. CBPO: 45.76 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CBPO' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 1.92  Med: 14.65 Max: 66.79
Current: 45.76
1.92
66.79
Price-to-Operating-Cash-Flow 27.20
CBPO's Price-to-Operating-Cash-Flow is ranked lower than
52% of the 191 Companies
in the Global Biotechnology industry.

( Industry Median: 21.01 vs. CBPO: 27.20 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CBPO' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 1.63  Med: 8.74 Max: 35.76
Current: 27.2
1.63
35.76
EV-to-EBIT 18.63
CBPO's EV-to-EBIT is ranked higher than
53% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. CBPO: 18.63 )
Ranked among companies with meaningful EV-to-EBIT only.
CBPO' s EV-to-EBIT Range Over the Past 10 Years
Min: 1.2  Med: 6.55 Max: 27.5
Current: 18.63
1.2
27.5
EV-to-EBITDA 17.12
CBPO's EV-to-EBITDA is ranked higher than
54% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. CBPO: 17.12 )
Ranked among companies with meaningful EV-to-EBITDA only.
CBPO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 1.1  Med: 5.8 Max: 25.8
Current: 17.12
1.1
25.8
PEG Ratio 1.25
CBPO's PEG Ratio is ranked higher than
67% of the 101 Companies
in the Global Biotechnology industry.

( Industry Median: 2.13 vs. CBPO: 1.25 )
Ranked among companies with meaningful PEG Ratio only.
CBPO' s PEG Ratio Range Over the Past 10 Years
Min: 0.42  Med: 1.22 Max: 2.05
Current: 1.25
0.42
2.05
Current Ratio 5.14
CBPO's Current Ratio is ranked higher than
60% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. CBPO: 5.14 )
Ranked among companies with meaningful Current Ratio only.
CBPO' s Current Ratio Range Over the Past 10 Years
Min: 1.03  Med: 2.71 Max: 6.57
Current: 5.14
1.03
6.57
Quick Ratio 3.16
CBPO's Quick Ratio is ranked lower than
55% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. CBPO: 3.16 )
Ranked among companies with meaningful Quick Ratio only.
CBPO' s Quick Ratio Range Over the Past 10 Years
Min: 0.54  Med: 1.67 Max: 4.27
Current: 3.16
0.54
4.27
Days Inventory 440.04
CBPO's Days Inventory is ranked lower than
91% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. CBPO: 440.04 )
Ranked among companies with meaningful Days Inventory only.
CBPO' s Days Inventory Range Over the Past 10 Years
Min: 280.18  Med: 423.98 Max: 490.33
Current: 440.04
280.18
490.33
Days Sales Outstanding 54.32
CBPO's Days Sales Outstanding is ranked higher than
74% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. CBPO: 54.32 )
Ranked among companies with meaningful Days Sales Outstanding only.
CBPO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.44  Med: 27.52 Max: 54.32
Current: 54.32
2.44
54.32
Days Payable 19.62
CBPO's Days Payable is ranked lower than
80% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. CBPO: 19.62 )
Ranked among companies with meaningful Days Payable only.
CBPO' s Days Payable Range Over the Past 10 Years
Min: 18.05  Med: 36.41 Max: 98.28
Current: 19.62
18.05
98.28

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.70
CBPO's 3-Year Average Share Buyback Ratio is ranked higher than
87% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. CBPO: -1.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CBPO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -5.9  Med: -2 Max: 1
Current: -1.7
-5.9
1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 69.39
CBPO's Price-to-Net-Cash is ranked lower than
94% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. CBPO: 69.39 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CBPO' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0  Med: 39.04 Max: 131.59
Current: 69.39
0
131.59
Price-to-Net-Current-Asset-Value 11.08
CBPO's Price-to-Net-Current-Asset-Value is ranked lower than
71% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. CBPO: 11.08 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CBPO' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0  Med: 11.73 Max: 695
Current: 11.08
0
695
Price-to-Tangible-Book 6.48
CBPO's Price-to-Tangible-Book is ranked lower than
62% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. CBPO: 6.48 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CBPO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.16  Med: 5.57 Max: 24.6
Current: 6.48
1.16
24.6
Price-to-Intrinsic-Value-Projected-FCF 2.67
CBPO's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
58% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 3.16 vs. CBPO: 2.67 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CBPO' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0  Med: 2.58 Max: 3.99
Current: 2.67
0
3.99
Price-to-Median-PS-Value 3.04
CBPO's Price-to-Median-PS-Value is ranked lower than
87% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. CBPO: 3.04 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CBPO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 0.95 Max: 4.35
Current: 3.04
0
4.35
Price-to-Peter-Lynch-Fair-Value 1.31
CBPO's Price-to-Peter-Lynch-Fair-Value is ranked higher than
70% of the 66 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. CBPO: 1.31 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
CBPO' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0  Med: 1.21 Max: 1.88
Current: 1.31
0
1.88
Price-to-Graham-Number 2.90
CBPO's Price-to-Graham-Number is ranked lower than
52% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 2.64 vs. CBPO: 2.90 )
Ranked among companies with meaningful Price-to-Graham-Number only.
CBPO' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0  Med: 2.12 Max: 11.5
Current: 2.9
0
11.5
Earnings Yield (Greenblatt) % 5.38
CBPO's Earnings Yield (Greenblatt) % is ranked higher than
84% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. CBPO: 5.38 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CBPO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.6  Med: 15.3 Max: 82.6
Current: 5.38
3.6
82.6
Forward Rate of Return (Yacktman) % 24.30
CBPO's Forward Rate of Return (Yacktman) % is ranked higher than
70% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 16.45 vs. CBPO: 24.30 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
CBPO' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 19.6  Med: 24.8 Max: 35.3
Current: 24.3
19.6
35.3

More Statistics

Revenue (TTM) (Mil) $347.0
EPS (TTM) $ 3.86
Beta1.70
Short Percentage of Float10.71%
52-Week Range $96.99 - 137.39
Shares Outstanding (Mil)27.20
» More Articles for CBPO

Headlines

Articles On GuruFocus.com
China Biologic Products to Report First Quarter of 2017 Financial Results Apr 21 2017 
Largest Insiders' Trades of the Week Jun 10 2016 
Insiders Are Selling Facebook and Ford Motor Mar 11 2016 
Weekly CFO Sells Highlight: ULTA, MIND, DG, PSA, CBPO, CNK Dec 20 2011 
Weekly CEO Sells Highlight: CTSH, CBPO, TCB, SRCL Sep 12 2010 

More From Other Websites
China Biologic Announces Effectiveness of Registration Statement and Mailing of Definitive Proxy... May 19 2017
Edited Transcript of CBPO earnings conference call or presentation 4-May-17 11:30am GMT May 08 2017
This Chinese Pharma Stock Has 20% Upside May 04 2017
Investor Network: China Biologic Products, Inc. to Host Earnings Call May 04 2017
China Biologic Products posts 1Q profit May 04 2017
China Biologic Reports Financial Results for the First Quarter of 2017 May 03 2017
China Biologic Products to Report First Quarter of 2017 Financial Results Apr 21 2017
China Biologic Products, Inc. – Value Analysis (NASDAQ:CBPO) : April 12, 2017 Apr 12 2017
China Biologic Products, Inc. breached its 50 day moving average in a Bullish Manner : CBPO-US :... Apr 11 2017
ETFs with exposure to China Biologic Products, Inc. : April 7, 2017 Apr 07 2017
China Biologic Products, Inc. :CBPO-US: Earnings Analysis: Q4, 2016 By the Numbers : March 2, 2017 Mar 02 2017
Edited Transcript of CBPO earnings conference call or presentation 24-Feb-17 12:30pm GMT Feb 24 2017
China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2016 Feb 23 2017
China Biologic Products to Report Fourth Quarter and Fiscal Year 2016 Financial Results Feb 14 2017
New Strong Sell Stocks for January 30th Jan 30 2017
China Biologic Products, Inc. – Value Analysis (NASDAQ:CBPO) : January 27, 2017 Jan 27 2017
China Biologic Products, Inc. breached its 50 day moving average in a Bullish Manner : CBPO-US :... Jan 26 2017
China Biologic to Build New Collection Station and New Branch Collection Facility in Shandong... Jan 06 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat